Cancer BiologyFrontiers in OncologyPeer-reviewed
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
H. Lang, C. Beraud, L. Cabel…·T. Massfelder
The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.
DOI 10.3389/fonc.2022.930731